• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Citius Oncology Inc.

    9/5/24 9:23:54 AM ET
    $CTOR
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CTOR alert in real time by email
    SC 13G/A 1 ef20035496_sc13ga.htm SC 13G/A

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

    TenX Keane Acquisition
    (Name of Issuer)

    Ordinary Shares, par value $0.0001 per share
    (Title of Class of Securities)

    G8708L104
    (CUSIP Number)

    August 2, 2024
    (Date of Event which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒  Rule 13d-1(b)

    ☐  Rule 13d-1(c)

    ☐  Rule 13d-1(d)

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



    SCHEDULE 13G
     
     
    CUSIP No.
    G8708L104

    1
    NAMES OF REPORTING PERSONS
     
     
    Wolverine Asset Management, LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Illinois
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     

     
     
     
     
    6
    SHARED VOTING POWER
     
     
    0
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     

     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    0
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    0
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    0%
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IA
     
     
     
     

    Page 2 of 10

     
    CUSIP No.
    G8708L104

    1
    NAMES OF REPORTING PERSONS
     
     
    Wolverine Holdings, L.P.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Illinois
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     

     
     
     
     
    6
    SHARED VOTING POWER
     
     
    0
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     

     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    0
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    0
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    0%
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    HC
     
     
     
     

    Page 3 of 10

     
    CUSIP No.
    G8708L104

    1
    NAMES OF REPORTING PERSONS
     
     
    Wolverine Trading Partners, Inc.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Illinois
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     

     
     
     
     
    6
    SHARED VOTING POWER
     
     
    0
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     

     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    0
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    0
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    0%
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    CO/HC
     
     
     
     

    Page 4 of 10

     
    CUSIP No.
    G8708L104

    1
    NAMES OF REPORTING PERSONS
     
     
    Christopher L. Gust
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    US Citizen
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     

     
     
     
     
    6
    SHARED VOTING POWER
     
     
    0
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     

     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    0
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    0
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    0%
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IN/HC
     
     
     
     

    Page 5 of 10

     
    CUSIP No.
    G8708L104

    1
    NAMES OF REPORTING PERSONS
     
     
    Robert R. Bellick
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    US Citizen
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     

     
     
     
     
    6
    SHARED VOTING POWER
     
     
    0
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     

     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    0
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    0
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    0%
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IN/HC
     
     
     
     

    Page 6 of 10

    Item 1.
     
    (a)
    Name of Issuer:
     
    TenX Keane Acquisition
     
    (b)
    Address of Issuer’s Principal Executive Offices:
     
    420 Lexington Avenue, Suite 2446
    New York, NY 10170
     
    Item 2.
     
    (a)
    Name of Person Filing:
     
    Wolverine Asset Management, LLC
    Wolverine Holdings, L.P.
    Wolverine Trading Partners, Inc.
    Christopher L. Gust
    Robert R. Bellick
     
    (b)
    Address of Principal Business Office or, if None, Residence:
     
    c/o Wolverine Asset Management, LLC
    175 West Jackson Boulevard, Suite 340
    Chicago, IL 60604
     
    (c)
    Citizenship:
     
    Wolverine Asset Management, LLC — Illinois
    Wolverine Holdings, L.P. — Illinois
    Wolverine Trading Partners, Inc. — Illinois
    Christopher L. Gust — US Citizen
    Robert R. Bellick — US Citizen
     
    (d)
    Title and Class of Securities:
     
    Ordinary Shares, par value $0.0001 per share.
     
    (e)
    CUSIP No.:
     
    G8708L104
     
    Item 3.
    If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     
    (a)
    ☐
    Broker or dealer registered under Section 15 of the Act;
           
     
    (b)
    ☐
    Bank as defined in Section 3(a)(6) of the Act;
           
     
    (c)
    ☐
    Insurance company as defined in Section 3(a)(19) of the Act;

    Page 7 of 10

     
    (d)
    ☐
    Investment company registered under Section 8 of the Investment Company Act of 1940;
           
     
    (e)
    ☒
    An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
           
     
    (f)
    ☐
    An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
           
     
    (g)
    ☒
    A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
           
     
    (h)
    ☐
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
     
    (i)
    ☐
    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;
           
     
    (j)
    ☐
    A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);
           
     
    (k)
    ☐
    Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
     

    Item 4.
    Ownership
     
    (a) Amount Beneficially Owned:
     
    Wolverine Asset Management, LLC (“WAM”) is an investment manager and has voting and dispositive power over 0 ordinary shares of the Issuer. The sole member and manager of WAM is Wolverine Holdings, L.P. (“Wolverine Holdings”). Robert R. Bellick and Christopher L. Gust may be deemed to control Wolverine Trading Partners, Inc. (“WTP”), the general partner of Wolverine Holdings.
     
    (b)
    Percent of Class:  0%
     
    WAM may be deemed the beneficial owner of 0% of the Issuer’s outstanding ordinary shares and each of Wolverine Holdings, WTP, Mr. Bellick, and Mr. Gust may be deemed the beneficial owner of 0% of the Issuer’s outstanding ordinary shares.
     
    (c)
    Number of shares as to which such person has:
     
      (i)
    Sole power to vote or to direct the vote:
     
      (ii)
    Shared power to vote or to direct the vote:
     
    WAM has shared power to vote or direct the vote of 0 ordinary shares of the Issuer, and each of Wolverine Holdings, WTP, Mr. Bellick, and Mr. Gust has shared power to vote or direct the vote of 0 ordinary shares of the Issuer, in each case as set forth in Item 4(a) above.
     

    (iii)
    Sole power to dispose or to direct the disposition of:
     

    (iv)
    Shared power to dispose or to direct the disposition of:
     
    WAM has shared power to dispose or direct the disposition of 0 ordinary shares of the Issuer, and each of Wolverine Holdings, WTP, Mr. Bellick, and Mr. Gust has shared power to dispose or direct the disposition of 0 ordinary shares of the Issuer, in each case as set forth in Item 4(a) above.
     
    Item 5.
    Ownership of Five Percent or Less of a Class.

    Page 8 of 10

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [ X  ].
     
    Item 6.
    Ownership of more than Five Percent on Behalf of Another Person.
     
    Wolverine Flagship Fund Trading Limited is known to have the right to receive the receipt of dividends from, or the proceeds from the sale of, the ordinary shares of the Issuer covered by this statement that may be deemed to be beneficially owned by WAM.
     
    Item 7.
    Identification and classification of the subsidiary which acquired the security being reported on by the parent holding company or control person.
     
    Item 8.
    Identification and classification of members of the group.
     
    Item 9.
    Notice of Dissolution of Group.
     
    Item 10.
    Certifications.
     
    Page 9 of 10

    SIGNATURE
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
     
    Dated:  September 4, 2024
     
     
    Wolverine Asset Management, LLC
       
     
    /s/ Kenneth L. Nadel
     
    Signature
       
     
    Kenneth L. Nadel, Chief Operating Officer
     
    Name/Title
       
     
    Wolverine Holdings, L.P.
       
     
    /s/ Christopher L. Gust
     
    Signature
       
     
    Christopher L. Gust, Managing Director
     
    Name/Title
       
     
    Wolverine Trading Partners, Inc.
       
     
    /s/ Christopher L. Gust
     
    Signature
       
     
    Christopher L. Gust, Authorized Signatory
     
    Name/Title
       
     
    /s/ Christopher L. Gust
     
    Christopher L. Gust
       
     
    /s/ Robert R. Bellick
     
    Robert R. Bellick
     
    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative.  If the statement is signed on behalf of a person by his authorized representative (other than an executive officer or general partner of this filing person), evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference.  The name and any title of each person who signs the statement shall be typed or printed beneath his signature.
     
    Attention:  Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).
     
     
    Page 10 of 10

    Get the next $CTOR alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $CTOR

    DatePrice TargetRatingAnalyst
    11/27/2024$3.00Buy
    Maxim Group
    More analyst ratings

    $CTOR
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Citius Oncology Announces Closing of $9.0 Million Public Offering

      CRANFORD, N.J., July 17, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (NASDAQ:CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. (NASDAQ:CTXR), today announced the closing of its "reasonable best-efforts" public offering of 6,818,182 shares of common stock of the Company and warrants to purchase shares of common stock at a public offering price of $1.32 per share. The warrants have an exercise price of $1.32 per share, are immediately exercisable upon issuance, and expire five years from the date of issuance. Gross proceeds from the offering, before deducting placement agent fees and other estimated offering expenses, are approximately $9.0

      7/17/25 4:30:00 PM ET
      $CTOR
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citius Oncology Announces Pricing of $9.0 Million Public Offering

      CRANFORD, N.J., July 16, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (NASDAQ:CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. (NASDAQ:CTXR), today announced the pricing of its "reasonable best-efforts" public offering of 6,818,182 shares of common stock of the Company and warrants to purchase shares of common stock at a public offering price of $1.32 per share. The warrants will have an exercise price of $1.32 per share, will be immediately exercisable upon issuance, and will expire five years from the date of issuance. Gross proceeds from the offering, before deducting placement agent fees and other estimated offering expenses, are expec

      7/16/25 9:15:00 AM ET
      $CTOR
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Citius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora

      Agreement with global pharmaceutical solutions provider enhances commercial infrastructure and reinforces launch readiness for FDA-approved immunotherapy LYMPHIR™ CRANFORD, N.J., July 15, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (NASDAQ:CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. (NASDAQ:CTXR), today announced the execution of a distribution services agreement with Cencora (formerly AmerisourceBergen), a global pharmaceutical services company. This agreement marks another significant step forward in the Company's commercial launch strategy for LYMPHIR (denileukin diftitox-cxdl), its FDA-approved immunotherapy for relapsed or refractory cutaneous T

      7/15/25 8:32:00 AM ET
      $CTOR
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTOR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Maxim Group initiated coverage on Citius Oncology with a new price target

      Maxim Group initiated coverage of Citius Oncology with a rating of Buy and set a new price target of $3.00

      11/27/24 8:17:22 AM ET
      $CTOR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTOR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Mayersohn Joel David

      4 - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)

      12/16/24 5:05:14 PM ET
      $CTOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Holuka Eugene Myron

      4 - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)

      12/16/24 4:09:27 PM ET
      $CTOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Secretary Holubiak Myron Z

      4 - CITIUS ONCOLOGY, INC. (0001851484) (Issuer)

      12/16/24 4:09:06 PM ET
      $CTOR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTOR
    Leadership Updates

    Live Leadership Updates

    See more
    • Amid NCI Budget Fears, Emerging Oncology Stocks Gain Attention

      Equity Insider News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, July 8, 2025 /PRNewswire/ -- Equity Insider News Commentary – As cancer rates climb and drug costs continue to soar, pressure is mounting on the private sector to drive innovation. Now, cancer experts are alarmed over a "gut wrenching" plan from the U.S. government to cut nearly 40% of National Cancer Institute funding, even as the price of oncology treatments pushes new limits—raising urgent concerns about access and affordability. In this shifting landscape, investors are turning their attention to a new wave of biotechs and specialty care providers developing breakthrough therapies and smarter care mo

      7/8/25 10:25:00 AM ET
      $CELC
      $CTOR
      $EXEL
      $ONCY
      Medical Specialities
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Biotechnology: Biological Products (No Diagnostic Substances)
    • The $900 Billion Question: Who Will Deliver the Next Cancer Breakthrough?

      USA News Group News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 26, 2025 /PRNewswire/ -- USA News Group News Commentary – With analysts forecasting the global oncology drug market to surpass US$900 billion by 2034, investor interest in cancer-focused biotechs is rapidly intensifying. ResearchAndMarkets and Vision Research Reports both point to strong double-digit growth, citing surging demand for next-gen diagnostics and immunotherapies. Yet even as market potential grows, the U.S. public health sector is facing potential setbacks. Budget proposals suggest National Cancer Institute (NCI) funding could be slashed by up to 40%, while Bloomberg highlights concerns 

      6/26/25 11:44:00 AM ET
      $ADCT
      $CTOR
      $ONCY
      $OSTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • After Major Oncology Conference, All Eyes Turn to Industry Innovation

      USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, June 12, 2025 /PRNewswire/ -- After the close of the world's largest cancer conference (the 2025 American Society of Clinical Oncology annual meeting), doctors, scientists, and researchers are optimistic, especially in the fields of immunotherapy, Car T-cell therapy, liquid biopsies, breast cancer, AI, and even exercise. However, with reports coming out that the current US administration could drastically reduce funding of the National Cancer Institute (NCI) by nearly 40%, the market is looking towards the private sector to pick up the slack and continue to make advancements in cancer treatment. For inv

      6/12/25 9:00:00 AM ET
      $CAH
      $CTOR
      $CTXR
      $ONCY
      Other Pharmaceuticals
      Health Care
      Biotechnology: Pharmaceutical Preparations

    $CTOR
    SEC Filings

    See more
    • Citius Oncology Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

      8-K - CITIUS ONCOLOGY, INC. (0001851484) (Filer)

      7/18/25 8:01:46 AM ET
      $CTOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Citius Oncology Inc.

      EFFECT - CITIUS ONCOLOGY, INC. (0001851484) (Filer)

      7/17/25 12:15:15 AM ET
      $CTOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 424B4 filed by Citius Oncology Inc.

      424B4 - CITIUS ONCOLOGY, INC. (0001851484) (Filer)

      7/16/25 9:21:46 PM ET
      $CTOR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTOR
    Financials

    Live finance-specific insights

    See more
    • Citius Pharmaceuticals, Inc. Reports Fiscal Full Year 2024 Financial Results and Provides Business Update

      Clinical and regulatory success in 2024 expected to drive value in 2025 CRANFORD, N.J., Dec. 27, 2024 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (NASDAQ:CTXR), a biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products today reported business and financial results for the fiscal full year ended September 30, 2024. Fiscal Full Year 2024 Business Highlights and Subsequent Developments Achieved U.S. Food and Drug Administration (FDA) approval of LYMPHIR™ (denileukin diftitox-cxdl), an immunotherapy for the treatment of adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL);Advanced ma

      12/27/24 5:00:00 PM ET
      $CTOR
      $CTXR
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CTOR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Citius Oncology Inc.

      SC 13G/A - CITIUS ONCOLOGY, INC. (0001851484) (Subject)

      11/6/24 5:08:07 PM ET
      $CTOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Citius Oncology Inc.

      SC 13G/A - CITIUS ONCOLOGY, INC. (0001851484) (Subject)

      9/5/24 9:23:54 AM ET
      $CTOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Citius Oncology Inc.

      SC 13D - CITIUS ONCOLOGY, INC. (0001851484) (Subject)

      8/16/24 4:34:29 PM ET
      $CTOR
      Biotechnology: Pharmaceutical Preparations
      Health Care